一覧に戻る

タイトル
  • en Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats.
作成者
アクセス権 open access
主題
  • MeSH en Administration, Oral
  • MeSH en Animals
  • MeSH en Aqueous Humor/drug effects
  • MeSH en Aqueous Humor/immunology
  • MeSH en Benzamides/pharmacology
  • MeSH en Benzamides/therapeutic use
  • MeSH en Chemokine CCL2/genetics
  • MeSH en Chemokine CCL2/immunology
  • MeSH en Dose-Response Relationship, Drug
  • MeSH en Endotoxins
  • MeSH en Gene Expression/drug effects
  • MeSH en I-kappa B Kinase/antagonists & inhibitors
  • MeSH en I-kappa B Kinase/metabolism
  • MeSH en Injections, Intraperitoneal
  • MeSH en Male
  • MeSH en NF-kappa B/genetics
  • MeSH en NF-kappa B/immunology
  • MeSH en Neutrophil Infiltration/drug effects
  • MeSH en Phosphorylation/drug effects
  • MeSH en Prodrugs/pharmacology
  • MeSH en Prodrugs/therapeutic use
  • MeSH en Protein Kinase Inhibitors/pharmacology
  • MeSH en Protein Kinase Inhibitors/therapeutic use
  • MeSH en Rats
  • MeSH en Rats, Inbred Lew
  • MeSH en Tumor Necrosis Factor-alpha/genetics
  • MeSH en Tumor Necrosis Factor-alpha/immunology
  • MeSH en Uveitis/chemically induced
  • MeSH en Uveitis/drug therapy
  • MeSH en Uveitis/immunology
  • MeSH en Uveitis/pathology
  • NDC 496
内容注記
  • Abstract en Purpose: Endotoxin-induced uveitis (EIU) is an animal model for acute ocular inflammation. Several substances play major roles in the development of inflammatory changes in EIU, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6. These inflammatory cytokines trigger the degradation of IκB by activating IκB kinases (IKKs). Released nuclear factor kappaB (NFκB) subsequently translocates to the nucleus, where NFκB expresses its proinflammatory function. IMD-0354, N-(3,5-Bis-trifluoromethylphenyl)-5-chloro-2-hydroxybenzamide, selectively inhibits IKKβ, particularly when induced by proinflammatory cytokines, such as TNF-α and IL-1β. In the present study, we examined whether IKKβ inhibition has therapeutic effects on EIU by using IMD-0354 and its prodrug IMD-1041. Methods: Six-week-old male Lewis rats were used. EIU was induced with subcutaneous injections of 200 μg of lipopolysaccharide (LPS) from Escherichia coli that had been diluted in 0.1 ml of phosphate-buffered saline. IMD-0354 was administered intraperitoneally at 30, 10, 3, or 0 mg/kg, suspended in 1.0 ml of 0.5% carboxymethyl cellulose sodium. The prodrug IMD-1041 (100 mg/kg) was also administered orally. The rats were euthanized 24 h after LPS injection, and EIU severity was evaluated histologically. The number of infiltrating cells and the protein, TNF-α, and monocyte chemoattractant protein-1 (MCP-1) concentrations in the aqueous humor were determined. TNF-α and MCP-1 concentrations were quantified with enzyme-linked immunosorbent assay. Eye sections were also stained with anti-NFκB and phosphorylated I-κBα antibodies. Results: The number of infiltrating cells in aqueous humor was 53.6±9.8×105, 72.5±17.0×105, 127.25±32.0×105, and 132.0±25.0×105 cells/ml in rats treated with 30, 10, 3, or 0 mg/kg of IMD-0354, respectively. The total protein concentrations of aqueous humor were 92.6±3.1 mg/ml, 101.5±6.8 mg/ml, 112.6±1.9 mg/ml, and 117.33±1.8 mg/ml in rats treated with 30, 10, 3, and 0 mg/kg of IMD-0354, respectively. Infiltrating cells and protein concentrations were significantly decreased by treatment with IMD-0354 (p<0.01). IMD-0354 treatment significantly reduced the concentration of TNF-α (p<0.05) and MCP-1 (p<0.01) in aqueous humor. The number of NFκB positive nuclei was reduced when treated with IMD-0354. Furthermore, IMD-0354-treated EIU rats showed only background levels of phosphorylated I-κBα; however, it was strongly expressed in the iris-ciliary body cell cytoplasm of the IMD-0354 untreated EIU rats. Oral administration of IMD-1041 also decreased the cell number (p<0.01) and protein concentration (p<0.05) of aqueous humor in EIU. Conclusions: Acute uveitis was ameliorated by inhibition of IKKβ in rats. IMD-0354 and its prodrug IMD-1041 seem to be promising candidates for treating intraocular inflammation/uveitis.
出版者 en Molecular Vision
日付
    Issued2012-10-20
言語
  • eng
資源タイプ journal article
出版タイプ VoR
資源識別子 HDL http://hdl.handle.net/2115/54616
関連
  • PMID 23112571
収録誌情報
    • PISSN 1090-0535
    • NCID AA12037116
      • en Molecular vision
      • 18 開始ページ2586 終了ページ2597
ファイル
コンテンツ更新日時 2023-07-26